266 related articles for article (PubMed ID: 25032733)
1. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.
Shipitsin M; Small C; Choudhury S; Giladi E; Friedlander S; Nardone J; Hussain S; Hurley AD; Ernst C; Huang YE; Chang H; Nifong TP; Rimm DL; Dunyak J; Loda M; Berman DM; Blume-Jensen P
Br J Cancer; 2014 Sep; 111(6):1201-12. PubMed ID: 25032733
[TBL] [Abstract][Full Text] [Related]
2. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
3. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil.
Kobus T; Hambrock T; Hulsbergen-van de Kaa CA; Wright AJ; Barentsz JO; Heerschap A; Scheenen TW
Eur Urol; 2011 Nov; 60(5):1074-80. PubMed ID: 21419565
[TBL] [Abstract][Full Text] [Related]
4. Role of tumor-associated macrophages in the Hexim1 and TGFβ/SMAD pathway, and their influence on progression of prostatic adenocarcinoma.
Ok Atılgan A; Özdemir BH; Akçay EY; Ataol Demirkan Ö; Tekindal MA; Özkardeş H
Pathol Res Pract; 2016 Feb; 212(2):83-92. PubMed ID: 26608417
[TBL] [Abstract][Full Text] [Related]
5. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
[TBL] [Abstract][Full Text] [Related]
6. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
7. Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours.
Corcoran NM; Hovens CM; Hong MK; Pedersen J; Casey RG; Connolly S; Peters J; Harewood L; Gleave ME; Goldenberg SL; Costello AJ
BJU Int; 2012 Mar; 109(5):660-4. PubMed ID: 21895937
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting prostatic biopsy Gleason sum under grading.
Stackhouse DA; Sun L; Schroeck FR; Jayachandran J; Caire AA; Acholo CO; Robertson CN; Albala DM; Polascik TJ; Donatucci CF; Maloney KE; Moul JW
J Urol; 2009 Jul; 182(1):118-22; discussion 123-4. PubMed ID: 19447436
[TBL] [Abstract][Full Text] [Related]
9. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort.
Hambrock T; Hoeks C; Hulsbergen-van de Kaa C; Scheenen T; Fütterer J; Bouwense S; van Oort I; Schröder F; Huisman H; Barentsz J
Eur Urol; 2012 Jan; 61(1):177-84. PubMed ID: 21924545
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
[TBL] [Abstract][Full Text] [Related]
11. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy.
Wolters T; Vissers KJ; Bangma CH; Schröder FH; van Leenders GJ
BJU Int; 2010 Jul; 106(2):280-6. PubMed ID: 19888978
[TBL] [Abstract][Full Text] [Related]
12. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study.
Ström P; Kartasalo K; Olsson H; Solorzano L; Delahunt B; Berney DM; Bostwick DG; Evans AJ; Grignon DJ; Humphrey PA; Iczkowski KA; Kench JG; Kristiansen G; van der Kwast TH; Leite KRM; McKenney JK; Oxley J; Pan CC; Samaratunga H; Srigley JR; Takahashi H; Tsuzuki T; Varma M; Zhou M; Lindberg J; Lindskog C; Ruusuvuori P; Wählby C; Grönberg H; Rantalainen M; Egevad L; Eklund M
Lancet Oncol; 2020 Feb; 21(2):222-232. PubMed ID: 31926806
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome.
Cattrini C; Rubagotti A; Nuzzo PV; Zinoli L; Salvi S; Boccardo S; Perachino M; Cerbone L; Vallome G; Latocca MM; Zanardi E; Boccardo F
Clin Genitourin Cancer; 2018 Dec; 16(6):e1257-e1265. PubMed ID: 30170989
[TBL] [Abstract][Full Text] [Related]
14. An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study.
Pantanowitz L; Quiroga-Garza GM; Bien L; Heled R; Laifenfeld D; Linhart C; Sandbank J; Albrecht Shach A; Shalev V; Vecsler M; Michelow P; Hazelhurst S; Dhir R
Lancet Digit Health; 2020 Aug; 2(8):e407-e416. PubMed ID: 33328045
[TBL] [Abstract][Full Text] [Related]
15. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization.
Tamimi Y; van der Poel HG; Karthaus HF; Debruyne FM; Schalken JA
Br J Cancer; 1996 Aug; 74(4):573-8. PubMed ID: 8761372
[TBL] [Abstract][Full Text] [Related]
17. Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness.
Moen LV; Ramberg H; Zhao S; Grytli HH; Sveen A; Berge V; Skotheim RI; Taskén KA; Skålhegg BS
Urol Oncol; 2017 Mar; 35(3):111.e1-111.e8. PubMed ID: 27838142
[TBL] [Abstract][Full Text] [Related]
18. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
[TBL] [Abstract][Full Text] [Related]
19. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
Khani F; Epstein JI
Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
[TBL] [Abstract][Full Text] [Related]
20. Pre-biopsy 3-Tesla MRI and targeted biopsy of the index prostate cancer: correlation with robot-assisted radical prostatectomy.
Patel U; Dasgupta P; Challacombe B; Cahill D; Brown C; Patel R; Kirby R
BJU Int; 2017 Jan; 119(1):82-90. PubMed ID: 27153933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
